

Lupin and Aspen Sign TB Deal

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------------	-------------------	-----------------------------	------------------------------

Mumbai, Sep 26, 2005: Lupin Limited and Aspen Pharmacare of South Africa have entered into an agreement to collaborate for TB related products market in the Republic of South Africa. The agreement involves cooperation in the areas of technology, manufacture and marketing. The arrangement would leverage the considerable expertise in technology that Lupin has in the area of cures for TB and Aspen's considerable marketing / technical capabilities. The current market size for TB drugs in South Africa is estimated at approx. USD 15 Million on per annum.

The arrangement envisages Aspen making milestone payments aggregating USD 2 Million to Lupin and profit sharing between the two partners.

Dr. K. K. Sharma, Managing Director, Lupin Limited commented, "This is a great opportunity for Lupin and Aspen to bring cost effective TB drugs to the growing South African market. We are delighted about our relationship with Aspen and we would like to see the scope expand over time".

Stephen Saad, Aspen Group Chief Executive said, "The agreement enhances South Africa and Aspen's ability to respond to the growing TB pandemic that continues to affect all sectors of society. HIV and AIDS have substantially raised TB infection rates in South Africa, thereby placing immense pressure on the country's healthcare resources. Aspen also previously received licenses for multi-drug resistant TB drugs from Eli Lilly. These combined deals complement Aspen's strength in the TB environment. Consequently Aspen is the only pharmaceutical manufacturer in the country to offer both first and second line TB treatments and Aspen is the continent's leader in providing pharmaceutical solutions for poverty-related diseases."

About Lupin

Headquartered in Mumbai Lupin (<http://www.lupinworld.com>) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion 11 of Lupin's plants have been approved by the USFDA and two facilities have been approved by the UKMHRA

About Aspen

Aspen is the southern hemisphere's largest generic pharmaceutical manufacturer and a global leader in generic ARVs. Aspen is also acknowledged as Africa's largest pharmaceutical manufacturer and as a major supplier of branded pharmaceutical and healthcare products to southern African and selected international markets.

Aspen has an extensive basket of quality, effective and affordable products in the branded, generic, over-the-counter, personal care, fast moving consumer goods, nutraceutical and infant milk formula categories.

Aspen became the world's first pharmaceutical manufacturer to be granted US Food and Drug Administration (FDA) approval to manufacture combination therapy generic anti-retrovirals (ARVs) in a co-packed form. This was enabled through voluntary licences from GlaxoSmithKline and Boehringer Ingleheim and underscores Aspen's scientific and technical capabilities, its manufacturing and quality standards, and GMP compliances.

Aspen's off shore subsidiaries contribute toward the Group's strategy of establishing a presence in selected geographic areas. Co-Pharma operates in the UK market, while UK based Aspen Resources is an intellectual property owning subsidiary of Aspen Holdings. Aspen Pharmacare Australia continues to complement the Aspen Group's off shore strategy of increased growth in selected off-shore territories and it is an extension of the Group's worldwide network of strategic alliances offering a range of products in niche market areas.

For more information about Aspen, click on www.aspenpharma.com

For further information contact:

Raju Kane

The Source

Mobile: +91 98200 45656

E-mail: mail@sourcepr.com